Oct 12 (Reuters) – Bristol Myers Squibb said on Monday its experimental drug met the main goal of a late-stage trial in patients with idiopathic pulmonary fibrosis, a serious lung-scarring disease. (
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
GERMAN CHANCELLOR MERZ: I WILL PROPOSE TO THE PRESIDENT TODAY THAT SCHWEITZER BE APPOINTED AS…
VIDEO SHOWS: HIGHLIGHTS OF THE ATP 1000 SHANGHAI MASTERS RESENDING WITH COMPLETE SCRIPT SHOWS: SHANGHAI,…
Surat (Gujarat) [India], October 12: ArcelorMittal Nippon Steel India (AM/NS India), a joint venture between…
BRUSSELS, Oct 12 (Reuters) - The European Commission is set to lay out potential trade defence…
Oct 12 (Reuters) - Norway's data protection authority has fined Microsoft's adtech unit Xandr 92 million…
ABUJA, Oct 12 (Reuters) - Gunmen ambushed a convoy of traders travelling to a market…